权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

IMPACC-MEDVAMC

基本信息

批准号：
10265764
负责人：
DAVID B CORRY
金额：
$ 32.8万
依托单位：
BAYLOR COLLEGE OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-01 至 2023-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10265764
关键词：
Allergic Allergic inflammation Animal Model Antifungal Agents Asthma B-Lymphocytes Binding Biological Assay Blood Coagulation Factor Blood coagulation Cells Chronic Cleaved cell Coagulants Coin Data Development Diagnosis Disease Dissection Endogenous Factors Environment Epithelial Cells Fibrinogen Fungal Spores Growth Human ITGAM gene ITGB2 gene Immune Immune System Diseases Immune response Immunity In Vitro Individual Inhalation Innate Immune Response Integrins Link Lower respiratory tract structure Lung Lung Inflammation Macrophage-1 Antigen Mediating Membrane Molds Molecular Mucous Membrane Mus Mutation Mycoses Pathogenesis Peptide Hydrolases Peripheral Blood Mononuclear Cell Phenotype Physiological Prevalence Proteins Prothrombin Reproduction spores Research Role STAT6 gene Sampling Severities Signal Transduction Sputum T-Lymphocyte TLR4 gene Testing Thrombin Tissue-Specific Gene Expression United States airway epithelium airway hyperresponsiveness allergic airway disease allergic airway inflammation asthma model asthmatic base chronic rhinosinusitis cohort fibrinopeptides gamma fungus human disease immune activation improved macrophage monocyte new therapeutic target novel patient subsets peripheral blood prevent response transcription factor transcriptome transcriptome sequencing

项目摘要

The objective of this supplement proposal is to understand the causes of airway diseases and thereby improve diagnosis and therapy of these common and debilitating of human ailments. The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study coordinates a national, multi-institution consortium, collecting detailed clinical data and biologic samples from hospitalized COVID-19 infected individuals, with the goal of identifying immune signatures/molecular biomarkers associated with clinical disease course, to allow the prioritization of clinical interventions and decision making. This supplement supports Baylor College of Medicine's and the Michael E. DeBakey VA Medical Center's (MEDVAMC) participation in IMPACC to facilitate screening and enrollment of inpatients with COVID-19. The proposed supplement research is within the scope of parent grant R01 AI135803, Fungal Pathogenesis of Moderate to Severe Asthma. This supplement is submitted for the purpose of Clinical data and sample collection/processing and the scope will be confined to patients confirmed to have COVID-19. Based on projected trends in COVID-19 disease in MEDVAMC, we estimate that up to 50 COVID-19 patients can be enrolled within 6 months. As enrollees will be followed for up to one year, the budget extends to 18 months. Data to be collected will consist of both primary and secondary clinical and mechanistic endpoints as well as exploratory clinical and mechanistic endpoints.

这项补充建议的目的是了解气道疾病的成因，从而改善诊断和治疗这些常见的和使人衰弱的人类疾病。免疫分型 COVID-19队列研究（IMPACC）中的评估协调了一个全国性的多机构联盟，从住院的COVID-19感染者中收集详细的临床数据和生物样本，识别与临床病程相关的免疫特征/分子生物标志物的目标，临床干预和决策的优先顺序。此补充支持贝勒学院医学和迈克尔E。DeBakey VA医疗中心（MEDVAMC）参与IMPACC，以促进新冠肺炎住院患者的筛查和入组。建议的补充研究在范围内母基金R 01 AI 135803，中度至重度哮喘的真菌发病机制。本补充提交用于临床数据和样本采集/处理，范围将限于确诊感染COVID-19的患者。根据MEDVAMC对COVID-19疾病的预测趋势，我们预计6个月内可招募多达50名COVID-19患者。作为注册者，预算延长至18个月。收集的数据将包括主要数据和次要数据临床和机制终点以及探索性临床和机制终点。